



Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation

Sigmund Silber^{1*}, Ajay J. Kirtane², Jorge A. Belardi³, Minglei Liu⁴, Sandeep Brar⁴, Martin Rothman⁴, and Stephan Windecker⁵

¹Heart Center at the Isar, Am Isarkanal 36, D-81379 Munich, Germany; ²Columbia University Medical Center/New York Presbyterian Hospital, New York, NY, USA;

³Cardiovascular Institute of Buenos Aires, Buenos Aires, Argentina; ⁴Medtronic, Inc., Santa Rosa, CA, USA; and ⁵University Hospital Foundation, Bern, Switzerland

Received 15 February 2013; revised 18 December 2013; accepted 13 January 2014

Aim

The optimal duration of dual antiplatelet therapy (DAPT) following the use of new generation drug-eluting stents is unknown.

Methods and results

The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme. Daily acetylsalicylate (ASA) and a thienopyridine for 6–12 months were prescribed. A DAPT interruption was defined as any interruption of ASA and/or a thienopyridine of >1 day; long interruptions were >14 days. Three groups were analysed: no interruption, interruption during the first month, and >1–12 months. There were 1069 (21.83%) patients with a DAPT interruption and 3827 patients with no interruption. Among the 166 patients in the 1-month interruption group, 6 definite/probable ST events occurred (3.61%; all long DAPT interruptions), and among the 903 patients in the >1–12 months (60% occurred between 6 and 12 months) interruption group, 1 ST event occurred (0.11%; 2-day DAPT interruption). Among patients with no DAPT interruption, 32 ST events occurred (0.84%). Rates of CD/TVMI were 6.84% in the 1-month long interruption group, 1.41% in the >1–12 months long interruption group, and 4.08% in patients on continuous DAPT.

Conclusion

In a pooled population of patients receiving an R-ZES, DAPT interruptions within 1 month are associated with a high risk of adverse outcomes. Dual antiplatelet therapy interruptions between 1 and 12 months were associated with low rates of ST and adverse cardiac outcomes. Randomized clinical trials are needed to determine whether early temporary or permanent interruption of DAPT is truly safe.

Clinical Trials.gov identifiers

NCT00617084; NCT00726453; NCT00752128; NCT00927940.

Keywords

Resolute zotarolimus-eluting stent • Dual antiplatelet therapy • Stent thrombosis

Introduction

The introduction of drug-eluting stents (DES) for the treatment of coronary artery disease has significantly reduced revascularization rates following percutaneous coronary intervention. However, the early enthusiasm for the first generation DES was tempered by

reports of an increased risk of late (30 days to 1 year) and very late (beyond 1 year) stent thrombosis (ST) with these devices.^{1–6}

These concerns, based on retrospective observational data with first generation sirolimus-eluting and paclitaxel-eluting stents,^{2,4} led to multi-disciplinary society guideline recommendations for extended duration of dual antiplatelet therapy (DAPT) in Europe (6–12 months)

* Corresponding author. Tel: +49 897421510, Fax: +49 8974215131, Email: sigmund@silber.com

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

and in the USA for at least 12 months DAPT following percutaneous coronary revascularization with a DES.^{7–13} These recommendations stemmed from historical observations that DAPT with a thienopyridine and acetylsalicylic acid (ASA) can effectively reduce ST.^{14–16} Furthermore, in several observational studies, early discontinuation of the thienopyridine, clopidogrel, was identified as a strong predictor for ST.^{17–19} However, the current clinical practice guidelines were limited by the lack of randomized controlled data comparing the efficacy and safety of 6 and 12 months of DAPT. More recently, three randomized studies regarding the duration of DAPT have been published but compare either 6 month vs. 1 or 2 year DAPT,^{20,21} or 1 year vs. 2 year DAPT.²² None showed superiority of the longer DAPT duration. There remains limited evidence addressing the risks and benefits of prolonged DAPT with newer generation DES that have demonstrated a superior safety profile and lower overall rate of ST when compared to with first generation DES.^{23–25} In fact, in light of recent safety data with newer generation DES platforms, some have questioned whether the risk of ST still represents a significant limitation to the use of DES.²⁶

Given the paucity of randomized trial data to define optimal duration of DAPT with new generation DES and the importance of minimizing risks for adverse events following percutaneous revascularization with DES, we undertook a detailed *post hoc* analysis to assess the impact of DAPT interruption on ST following implantation of the Resolute™ zotarolimus-eluting stent (R-ZES, Medtronic, Inc., Santa Rosa, CA, USA). Because ST is a rare event but is associated with serious clinical consequences,²⁷ the analysis also includes an assessment of cardiac death and target-vessel myocardial infarction (CD/TVMI) for patients with and without a DAPT interruption as well as additional details related to the DAPT interruption and ST.

Methods

Clinical data were pooled from four prospective multicenter clinical trials of the R-ZES; RESOLUTE-All Comers (R-AC, $n = 1140$), RESOLUTE-International (R-INT, $n = 2349$), RESOLUTE-Japan (R-J, $n = 100$), and RESOLUTE-US (R-US, $n = 1402$). The RESOLUTE First-in-Man (R-FIM) trial was not included because the required data on DAPT use were not collected in this trial. Across the entire RESOLUTE global clinical programme consistent methodology was employed to allow data from multiple trials to be pooled in order to provide more reliable estimates of the true risk of clinical safety events. Specifically, these clinical trials were conducted using similar data collection procedures, identical adjudication processes, and consistent endpoint definitions.^{28–31} Notably, the R-AC and R-INT trials included a large number of patients with complex clinical or lesion characteristics. All trials were 100% monitored with the exception of R-INT which was 25% monitored in the first year, and Clinical Event Committees were harmonized across the trials to ensure consistency in adjudication and comparability of the data from the different trials. All trials complied with the Declaration of Helsinki, were approved by the appropriate ethics committees for each site and informed consent was obtained from all patients.

All trials recommended ASA was to be given indefinitely and a thienopyridine (clopidogrel 75 mg daily or ticlopidine 250 mg twice daily) for a minimum of 6 months and optimally for 12 months. For the purposes of this analysis, patients must have had key DAPT data available including start and stop dates of the thienopyridine or ASA. Additionally, 34 patients who started DAPT more than a day after stent implantation were excluded from this analysis (including a single patient who had a ST event prior to the start of DAPT) (Figure 1).

A DAPT interruption was defined as either a temporary interruption of ASA and/or a thienopyridine (interruption of > 1 day), or a permanent discontinuation. Based on reports that the pharmacodynamics effects of thienopyridines on platelet aggregation can take up to 14 days to clear following DAPT interruption,³² patients with a DAPT interruption of longer than 14 days were also analysed. Reasons for DAPT interruptions were categorized as clinical, procedural, or patient non-adherence based on reasons checked on patient case report forms. The timing of the first interruption was used to classify patients into an interruption group; patients in whom a ST occurred while on DAPT were included in the non-interruption group even if there was a DAPT interruption after the event.

Stent thrombosis events were categorized according to the Academic Research Consortium (ARC) definitions.³³ The impact of DAPT interruption within the first year after stent implantation on 1 year definite and probable ST events was analysed by categorizing the timing of interruption into three groups: patients with no DAPT interruption, DAPT interruption during the first month (30 days), and DAPT interruption between 1 and 12 months (Figure 1). All the patients who had a DAPT interruption within 12 months of the PCI procedure were followed for a full year after the time of the DAPT interruption to fully assess risk for ST. The population utilized for DAPT interruption analyses was also used to assess the incidence of CD/TVMI based upon DAPT interruption status. Bleeding events, which were available for the subgroup of patients enrolled on the R-INT trial, were analysed in a similar fashion based upon DAPT interruption status.

Statistical methods

The three analysis groups were based on timing of DAPT interruption (no interruption, interruption in the first month, and interruption after 1 to 12 months following stent placement) and were pre-specified before the *post hoc* analysis was undertaken. Descriptive statistics for the baseline characteristics are provided. Categorical variables were reported as counts and percentages, and were assessed using Pearson's Chi-square test. Continuous variables were presented as means \pm SD and were compared using one-way analysis of variance. The Kaplan–Meier method was used to calculate the cumulative incidence of ST events, and the log-rank test was used to compare between-group differences. A two-sided P -value of < 0.05 was considered to indicate statistical significance. Data analysis was conducted independently by the Harvard Clinical Research Institute (Boston, MA, USA).

Results

There were 1069 (21.8%) patients who had a DAPT interruption and 3827 patients who continued DAPT with no interruption. Among patients with a DAPT interruption 166 (15.5%) interrupted in the first month, another 92 (8.6%) interrupted between 1 and 3 months, and 171 (16.0%) interrupted DAPT between 3 and 6 months (Figure 2). Among patients with a classifiable reason for DAPT interruption, temporary DAPT interruption was usually prior to a medical/dental/surgical procedure (42.2%) or for another clinical indication (12.8%), whereas permanently discontinued DAPT most often occurred because patients completed their prescribed course (46.0%) (Figure 3). Stent thrombosis events were evenly distributed across the different reasons for DAPT interruption.

Baseline patient and lesion characteristics of the 4896 patients included in the analysis are shown in Table 1. The incidence of diabetes ($\sim 30\%$) and acute coronary syndromes (overall $\sim 40\%$) was similar between the three groups; however, patients with a DAPT




Figure 1 Patient disposition according to dual antiplatelet therapy interruption status. DAPT, dual antiplatelet therapy; R-AC, RESOLUTE-All comers; R-INT, RESOLUTE-International; R-J, RESOLUTE-Japan; R-US, RESOLUTE-US.




Figure 2 Distribution of patients according to time of first dual antiplatelet interruption.

interruption in the first month were older and had lower left ventricular ejection fractions. In addition, these patients had more B2/C class lesions and smaller reference vessel diameter, but shorter lesion lengths.

Timing of stent thrombosis

In total, 39 cases of ST occurred during the first year following R-ZES implantation. Overall, 32 (82.1%) cases of ST occurred when patients were on DAPT and 7 (17.9%) ST events occurred when patients were




Table 1 Baseline demographic and lesion characteristics

Baseline characteristics	Never interrupted, n = 3827 patients	Interrupted first month, n = 166 patients	Interrupted >1–12 months, n = 903 patients	P-value
Age (years)	63.4 ± 10.8 (3827)	66.6 ± 12.0 (166)	65.5 ± 11.3 (903)	<0.001
History of smoking	59.1% (2261/3827)	53.0% (88/166)	58.4% (527/903)	0.289
Prior percutaneous coronary revascularization	30.7% (1176/3827)	27.1% (45/166)	33.1% (299/903)	0.204
Diabetes mellitus	29.6% (1134/3827)	32.5% (54/166)	31.8% (287/903)	0.354
Insulin dependent	8.5% (327/3827)	10.8% (18/166)	10.2% (92/903)	0.201
Prior MI	25.6% (974/3800)	22.7% (37/163)	27.1% (242/893)	0.435
Left ventricular ejection fraction <30%	1.8% (48/2630)	5.7% (6/105)	2.1% (14/671)	0.020
Lesion class B2/C	65.9% (3271/4960)	72.7% (152/209)	68.5% (791/1154)	0.040
ACS	42.4% (1621/3827)	42.2% (70/166)	40.0% (361/903)	0.427
STEMI	8.5% (327/3827)	8.4% (14/166)	6.9% (62/903)	0.255
NSTEMI	7.8% (297/3827)	7.8% (13/166)	8.3% (75/903)	0.861
Unstable angina	26.1% (997/3827)	25.9% (43/166)	24.8% (224/846)	0.744
Pre-procedure RVD (mm)	2.79 ± 0.51 (4767)	2.70 ± 0.56 (198)	2.76 ± 0.53 (1092)	0.010
Lesion length (mm)	15.93 ± 9.66 (4744)	14.77 ± 8.33 (198)	15.09 ± 8.95 (1091)	0.010
Number of stents per patient	1.56 ± 0.94 (3827)	1.53 ± 1.10 (166)	1.52 ± 0.90 (903)	0.615
Total stent length per patient (mm)	29.38 ± 19.56 (3826)	27.84 ± 22.49 (166)	27.83 ± 18.84 (903)	0.071
Stent diameter (mm)	2.95 ± 0.45 (6367)	2.93 ± 0.46 (271)	2.94 ± 0.45 (1467)	0.476

Data are presented as means ± SD or % (n/N).

off DAPT at the time of ST (Figure 4). Among the 29 ST events occurring early (within 30 days), 25 of these events occurred on DAPT and 4 occurred off DAPT. Among the 10 cases of late ST, 7 occurred on DAPT and 3 occurred off DAPT.

Dual antiplatelet therapy interruption

Among the 3827 patients with no DAPT interruption, there were 32 ST events (0.84%). Among patients with DAPT interruption,

166 patients interrupted DAPT in the first month, with 6 ST events occurring in this group (3.61%). Among 903 patients with a DAPT interruption between 1 and 12 months, one ST event occurred (0.11%). Kaplan–Meier estimates of the cumulative incidence of ST events showed a significant difference between patients interrupted in the first month and patients with a DAPT interruption between 1 and 12 months (log-rank $P < 0.001$; Figure 5). In addition to the ST assessment at 12 months, when the 1069 patients with any DAPT

interruption were followed for one full year after the time of DAPT interruption, no additional ST events were identified beyond the seven events described here.

Dual antiplatelet therapy interruption longer than 14 days

Among the 874 patients with a DAPT interruption longer than 14 days, 122 interrupted in the first month. All of the six ST events that occurred in the first month were in these patients who had a prolonged DAPT interruption. Among the 752 patients with a longer than 14 day DAPT interruption between 1 and 12 months, there was no ST event.




Figure 4 Timing of stent thrombosis regardless of time of dual antiplatelet therapy interruption. DAPT, dual antiplatelet therapy; ST, stent thrombosis.

Thienopyridine interruption

In patients with a DAPT interruption, the thienopyridine alone was interrupted in 662 (61.9%) patients; there were three total ST events in this group. Among patients interrupting thienopyridine only, 67 patients interrupted the thienopyridine within 1 month [with two ST events (3.0%)], and 595 patients interrupted the thienopyridine between 1 and 12 months [with one ST event (0.2%)].

Acetylsalicylate interruption

In patients with a DAPT interruption, the ASA alone was interrupted in 196 (18.3%) patients; there were four total ST events in this group. Among patients interrupting ASA only, 78 patients interrupted ASA within 1 month [with four ST events (5.1%)], and 118 patients interrupted ASA between 1 and 12 months (no ST events).

Simultaneous interruption

In patients with a DAPT interruption, simultaneous interruption of both the thienopyridine and ASA therapies occurred in 211 (19.7%) patients. Among these patients, 21 interrupted DAPT within the first month and 190 patients interrupted between 1 and 12 months. Notably, there were no ST events in either group.

Permanent discontinuation of dual antiplatelet therapy

Among patients with a DAPT interruption, there were 695 patients (65.0%) who stopped DAPT permanently; of these, 69 occurred within the first month. All four ST events among patients with permanent DAPT discontinuation occurred in patients who permanently discontinued DAPT within the first month.




Figure 5 Cumulative incidence of definite or probable stent thrombosis through 1 year after stent implantation according to dual antiplatelet therapy interruption status. ST, stent thrombosis.

Table 2 Details of stent thrombosis events in patients with dual antiplatelet therapy interruption within 1 year of PCI procedure

Patient	Time of interruption	Duration of interruption	Interrupted medication	Time of ST event (duration of interruption until ST)	ARC classification of ST event
DAPT interruption 0–1 month					
1	Day 1	Permanent ^a	ASA	Day 108 (108)	Probable
2	Day 1	Permanent ^b	ASA	Day 2 (2)	Probable
3	Day 3	33 days	ASA	Day 22 (20)	Definite
4	Day 2	Permanent ^b	Clopidogrel	Day 4 (3)	Probable
5	Day 2	Permanent	ASA	Day 5 (4)	Probable
6	Day 2	30 days	Clopidogrel	Day 32 (31)	Definite
DAPT interruption 1–12 months					
7	Day 69	2	Clopidogrel	Day 71(3)	Definite

^aPatient was permanently off DAPT for 108 days before ST event and death.

^bPatients died after ST event within 2–3 days of DAPT interruption.

Details of stent thrombosis events in dual antiplatelet therapy interrupted patients

Of the seven ST events that occurred in DAPT interrupted patients within 1 year after the interruption, three were definite and four were probable (Table 2). Two definite ST and four probable ST events were in patients who had a DAPT interruption within the first month. The median number of days to interruption following the PCI for all six patients in this group was 2 days.

For the single case of ARC definite ST that occurred in the interrupted group between 1 and 12 months, the patient had a history of ST prior to the PCI procedure and had two total occlusions close to the previously implanted stents that were treated during the PCI procedure (Table 2). The median number of days to interruption for all patients was 211 days.

Cardiac death/target-vessel myocardial infarction by dual antiplatelet therapy interruption longer than 14 days

Overall there were 4071 patients who never interrupted DAPT > 14 days or were on DAPT at the time of the CD or TVMI. Among patients who never interrupted DAPT longer than 14 days, the rate of CD/TVMI was 4.08% (166/4071). The rate of CD/TVMI was 6.84% in patients with a longer than 14 day DAPT interruption within the first month; lower rates of CD/TVMI occurred in patients interrupted longer than 14 days between 1–3, 3–6 and 6–12 months (Figure 6).

Bleeding outcomes

Of the 2309 patients from R-INT with bleeding data ascertained, 1896 patients had no DAPT interruption prior to any bleeding event; there were 34 bleeding events in these patients (1.79%). No patient who had a DAPT interruption within the first month (*n* = 56) had a bleeding event, and two bleeding events occurred in the 357 patients (0.56%) with a DAPT interruption from 1 to 12 months.




Figure 6 Distribution of patients with cardiac death or target-vessel myocardial infarction per interval of dual antiplatelet interruption longer than 14 days. The mean value for the grouped interruption interval of 1 to <12 months was 1.41%.

Discussion

In patients with stable coronary artery disease, current recommendations for DES call for a minimum of 6 months in the European^{7,8} and 12 months in the US guidelines.⁹ The recently revised American College of Cardiology Foundation/American Heart Association guidelines for management of ST-elevation myocardial infarction recommend 12 months DAPT duration and a strict minimum of 6 months following DES placement for these high-risk patients.¹⁰ In patients with acute coronary syndromes, both guidelines recommend DAPT for 12 months, irrespective of stent type.^{7–9,11–13} However, prolonged DAPT has been associated with higher bleeding rates,³⁴ and optimal DAPT duration with new generation DES is unknown. In this analysis, >4800 patients treated with the R-ZES,

we found that most ST events occurred within 30 days of the index procedure, irrespective of DAPT status. Moreover, DAPT interruptions beyond 30 days were associated with a low risk of ST and no increased risk of CD/TVMI.

Data from other newer generation stent platforms also show that the greatest risk of ST is within the first 30 days and that the risk of ST does not differ between patients on DAPT and off DAPT following this time point.³⁵ These data suggest that other factors such as procedural factors, implantation technique, and patient-related factors impacting the risk for ST are especially important during the first 30 days post-procedure.^{36–39} It is known that ~4–7% of patients undergoing PCI and stent placement will require non-cardiac surgery in each year after treatment and thus it is often unavoidable to interrupt DAPT before the 6–12 months post-procedure recommended.⁴⁰ For patients that interrupted DAPT in the current analysis, nearly all ST events (six of seven) occurred in patients who interrupted DAPT between 0 and 1 month and only one patient that interrupted DAPT after 1 and before 12 months had a ST.

While event numbers are small, interruption of DAPT after 1 month appeared to confer no additional risk for ST, compared with no interruption of DAPT. However, interruption of DAPT during the first month was associated with a greater risk of ST. The log-rank *P*-value for the difference in ST rates between patients interrupted between 1 and 12 months and patients interrupted within the first month is <0.0001, which would imply that the patients that interrupted between 1–12 months has a lower risk of ST than patients that interrupted within a month of R-ZES. These data do not address patients who may be at a higher risk for ST regardless of stent type but suggest that DAPT interruption after 1 month may not confer increased risk for ST, CD, or MI for many patients receiving a Resolute stent. While observational studies of the first generation DES consistently showed a correlation between early discontinuation of DAPT and higher rates of ST, it is not clear that the same observations apply to new generation DES such as the R-ZES, as evidenced by our observation that the rate of ST in patients with a DAPT interruption after 1 month is quite low.

It is also important to consider the role of duration of interruption. The thienopyridines, ticlopidine, and clopidogrel are pro-drugs metabolized in the liver to active metabolites that are non-competitive antagonists of the platelet adenosine diphosphate receptor, P2Y₁₂. Inhibition of platelet aggregation by these drugs is delayed until 24–48 h after administration, with maximal inhibition achieved after 3–5 days. Studies have shown that it takes up to 14 days for the platelet function to recover after DAPT withdrawal,³² which supports the relevance and importance of assessing ST status for subjects that interrupt for longer than 14 days given that a DAPT effect on platelet function could still be active during shorter interruption durations. Consistent with these data, the DAPT Study being conducted in over 20 000 subjects uses a duration of DAPT longer than 14 days to define compliance.⁴¹ In this analysis, no ST events occurred in patients with longer than 14 day interruption in the 1–12-month interruption group. All six ST events in patients with longer than 14 day interruption occurred in the 1-month interruption group.

When the reasons for DAPT interruption were investigated, we noted no difference in the incidence of ST according to reason for interruption although the small number of events precludes any

definitive conclusions. However a recently published observational study of over 5000 patients looking at cessation of DAPT and cardiac events after PCI observed a significantly greater risk for major adverse cardiac events when patients disrupted their therapy than when physicians chose to discontinue or interrupt DAPT.⁴²

Prolonged use of antiplatelet drugs is a known risk for bleeding events and there is evidence to suggest that for some patients, DAPT extension beyond 3 months confers no additional benefit in terms of reduction in ST events, but is associated with more major bleeding events.⁴³ Even mild-to-moderate bleeding events are associated with a poorer long-term prognosis compared with those patients without bleeding.⁴⁴ These results (1.79% bleeding with no DAPT interruption and 0.56% bleeding in DAPT interrupted patients) are consistent with observations that there is an increased risk for bleeding in the presence of DAPT.

In addition to the lack of safety benefit demonstrated with extended use of DAPT, there is increasing evidence to show comparable safety outcomes in terms of ST and cardiac death with a shorter DAPT duration than is currently recommended by guidelines. Analysis from multiple publications shows the greatest risk for ST and cardiac death is observed when DAPT interruption occurs within 30 days after stent implantation.^{17,45–48} These observations highlight the need for randomized controlled trials to evaluate the risk vs. benefit of very short (1 month) vs. longer durations of DAPT after DES implantation.

Cardiac death/target-vessel myocardial infarction

The clinical consequences of ST can be serious, with death and myocardial infarction being the most severe. A pooled analysis of multicentre coronary stent trials and registries has shown that ST is a rare but usually catastrophic event, frequently associated with a myocardial infarction or death. The use of DAPT for a period longer than 12 months in patients who had received DESs was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes in a previously randomized study.²² Although not all cardiac deaths and myocardial infarctions are ST-related, we analysed the occurrence of CD/TVMI in patients with and without a longer than 14 day DAPT interruption to provide a more inclusive assessment of ST. Results support the conclusion that the antiplatelet therapy discontinuation was not necessarily followed by major cardiovascular events, at least in patients with a prolonged DAPT interruption later than 1 month after stenting.

There are several possible mechanisms explaining the relative safety of the R-ZES. Pre-clinical studies of the Biolinx™ polymer blend used on the R-ZES demonstrate that the hydrophilic surface of this polymer coating does not induce an inflammatory response and provides excellent biocompatibility.⁴⁹ This observation was confirmed in a porcine coronary artery model showing minimal inflammation following implantation of the R-ZES.⁵⁰ Clinical studies have also supported the safety of ZES. For example, some of these findings might be explained by better neointimal coverage in the early post-implant period compared with earlier generation DES.^{51,52} In optical coherence tomography studies, most of the stent struts were covered with neointima at 3 months after R-ZES implantation

and the rates of malapposition ($0.7 \pm 2.2\%$) and thrombus (1/18, 5.6%) were quite low,⁵² and exposure of stent struts and thrombi was observed less frequently in patients undergoing PCI with ZES than in those undergoing PCI with SES at 9-month follow-up.⁵¹

Although 1 year of clinical follow-up may not be sufficient to assess the very late outcomes, the data presented here are meaningful given that the majority of the ST events occurs within the first year following stent implantation. Moreover, the optimal duration of DAPT might be different according to DES types. These data suggest for R-ZES, DAPT use for the first month after stent placement is important but the necessity for continued DAPT beyond this time is unclear. DES that can offer both safety and efficacy are desirable, especially for those who may need to stop DAPT early after DES implantation.

Limitations

This is a *post hoc* analysis of pooled datasets that may not reflect the higher ST risk likely to occur in routine clinical practice. Specifically, the RESOLUTE-Japan and RESOLUTE-US trials enrolled subjects likely to be at a lower risk for clinical events; however, the majority (70%) of the patients included in this analysis was taken from the RESOLUTE-International Registry ($n = 2349$) and the RESOLUTE-All Comers trial ($n = 1140$) which enrolled a high proportion of high-risk 'real world' patients. These results should not be overinterpreted in this observational database given that physicians may have appropriately selected those patients who could safely interrupt DAPT and the small number of ST events that occurred after R-ZES implantation. Additionally, most of the DAPT interruptions (often temporary and brief) occurred after 6 months making it difficult to sort out the exact role of nature of the association between DAPT interruptions and adverse clinical events. The generalized application of these results to the entire population demands careful attention given that a larger sample size and a randomized trial might be required to provide a definite answer regarding low frequency events such as ST. The findings reported here apply only to R-ZES. Because safety and efficacy differ according to the DES type, additional analyses that determine the feasibility of short duration DAPT after implantation of other DES are needed.

Conclusion

In a large pooled population of patients treated with an R-ZES, DAPT interruptions between 1 and 12 months were associated with low rates of ST and adverse cardiac outcomes. It would be inappropriate to suggest any changes to the ESC or ACC/AHA/SCAI guidelines for PCI post-stent implantation; however, the current analysis may provide reassurance for clinicians and patients implanted with an R-ZES who may need to interrupt or discontinue the medications before the recommended duration for a variety of unplanned reasons. Randomized clinical trials are needed to determine whether early temporary or permanent interruption of DAPT is truly safe.

Acknowledgements

The authors thank Lilian Lee, PhD, for analysis support, and Colleen Gilbert, PharmD for editorial support in the development of this manuscript.

Funding

This study was funded by Medtronic, Inc.

Conflict of interest: S.S. has received grant, travel, and analysis support from Medtronic; J.A.B. serves as an advisor to Medtronic; M.L., S.B., and M.R. are employees of Medtronic, Inc. All other authors have nothing to disclose.

References

- McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. *Lancet* 2004;**364**:1519–1521.
- Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. *N Engl J Med* 2007;**356**:998–1008.
- Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. *N Engl J Med* 2007;**356**:1020–1029.
- Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. *N Engl J Med* 2007;**356**:989–997.
- Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. *Circulation* 2007;**115**:1440–1455; discussion 1455.
- Daemen J, Simoons ML, Wijns W, Bagust A, Bos G, Bowen JM, Braunwald E, Camenzind E, Chevalier B, Dimario C, Fajadet J, Gitt A, Guagliumi G, Hillege HL, James S, Juni P, Kastrati A, Kloth S, Kristensen SD, Krucoff M, Legrand V, Pfisterer M, Rothman M, Serruys PW, Silber S, Steg PG, Tariah I, Wallentin L, Windecker SW, Aimonetti A, Alocco D, Baczynska A, Bagust A, Berenger M, Bos G, Boam A, Bowen JM, Braunwald E, Calle JP, Camenzind E, Campo G, Carlier S, Chevalier B, Daemen J, de Schepper J, Di Bisceglie G, Dimario C, Dobbels H, Fajadet J, Farb A, Ghislain JC, Gitt A, Guagliumi G, Hellbardt S, Hillege HL, Ten Hoedt R, Isaia C, James S, de Jong P, Juni P, Kastrati A, Klasen E, Kloth S, Kristensen SD, Krucoff M, Legrand V, Lekehal M, Lenarz L, Ni Mhullain F, Nagai H, Patteet A, Paunovic D, Pfisterer M, Potgieter A, Purdy I, Raveau-Landon C, Rothman M, Serruys PW, Silber S, Simoons ML, Steg PG, Tariah I, Ternstrom S, Van Wuytswinkel J, Waliszewski M, Wallentin L, Wijns W, Windecker SW. ESC forum on drug eluting stents European Heart House, Nice, 27–28 September 2007. *Eur Heart J* 2009;**30**:152–161.
- Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. *Eur Heart J* 2005;**26**:804–847.
- Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliquet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlot C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D, Guidelines ECP, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Committee ECG, Kolh P, Alfieri O, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouhe P, Reviewers D, Kearney P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, Brutel de la Riviere A, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Laufer G, Legrand V, Nashef SAM, Neumann F-J, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M. Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-thoracic Surgery (EACTS). *Eur Heart J* 2010;**31**:2501–2555.
- Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2011;**58**:e44–122.
- O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D,

- Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW. American College of Cardiology Foundation/American Heart Association Task Force on Practice G. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force On Practice Guidelines. *Circulation* 2013;**127**:e362–e425.
11. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2012;**60**:645–681.
 12. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S, Windecker S, Achenbach S, Badimov L, Bertrand M, Botker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyens L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011;**32**:2999–3054.
 13. Steg PG, James SK, Atar D, Badano LP, Blömlund-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-elevation myocardial infarction of the European Society of Cardiology. *Eur Heart J* 2012;**33**:2569–2619.
 14. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. *N Engl J Med* 1998;**339**:1665–1671.
 15. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (classics). *Circulation* 2000;**102**:624–629.
 16. Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann F-J, ten Berg JM, Schömig A, Kastrati A. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the intracoronary stenting and antithrombotic regimen: safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) study. *Am Heart J* 2009;**157**:620–624.e622.
 17. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. *J Am Coll Cardiol* 2006;**48**:2584–2591.
 18. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA* 2007;**297**:159–168.
 19. Iakovou I, Schmidt T, Bonizzi E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA* 2005;**293**:2126–2130.
 20. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R. Investigators PRDataGs-ILHS. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY). *Eur Heart J* 2013;**34**:909–919.
 21. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/promus versus cypher to reduce late loss after stenting (excellent) randomized, multicenter study. *Circulation* 2012;**125**:505–513.
 22. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. *N Engl J Med* 2010;**362**:1374–1382.
 23. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. *Lancet* 2010;**375**:201–209.
 24. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL, Investigators SI. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. *Circulation* 2009;**119**:680–686.
 25. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klaus V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Juni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. *Lancet* 2011;**378**:1940–1948.
 26. Stefanini G, Holmes DR. Drug-eluting coronary artery stents. *New Engl J Med* 2013;**368**:254–265.
 27. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. *Circulation* 2001;**103**:1967–1971.
 28. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. *N Engl J Med* 2010;**363**:136–146.
 29. Yeung AC, Leon MB, Jain A, Tolleson TR, Spriggs DJ, Mc Laurin BT, Popma JJ, Fitzgerald PJ, Cutlip DE, Massaro JM, Mauri L. Clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. *J Am Coll Cardiol* 2011;**57**:1778–1783.
 30. Neumann FJ, Widimsky P, Belardi JA. One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International registry. *EuroIntervention* 2012;**7**:1181–1188.
 31. Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers Trial. *Lancet* 2011;**377**:1241–1247.
 32. Kam PC, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. *Anaesthesia* 2003;**58**:28–35.
 33. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007;**115**:2344–2351.
 34. Tsai TT, Ho PM, Xu S, Powers JD, Carroll NM, Shetterly SM, Maddox TM, Rumsfeld JS, Margolis K, Go AS, Magid DJ. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO research network-stent registry (HMORN-stent). *Circ Cardiovasc Interv* 2010;**3**:230–235.
 35. Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, Wilburn O, Sudhir K, Simonton C, Hermiller JB. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after xience V implantation: results from the 8,061-patient Xience V United States study. *JACC Cardiovasc Interv* 2012;**5**:626–635.
 36. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dargatzis G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, Stone GW, Teirstein PS, Leon MB, Moses JW. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. *Circulation* 2004;**109**:1085–1088.
 37. Cheneau E, Leborgne L, Mintz GS, Kotani J, Pichard AD, Satler LF, Canos D, Castagna M, Weissman NJ, Waksman R. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. *Circulation* 2003;**108**:43–47.
 38. Alfonso F, Suarez A, Perez-Vizcaino MJ, Moreno R, Escaned J, Banuelos C, Jimenez P, Bernardo E, Angiolillo DJ, Hernandez R, Macaya C. Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. *J Am Coll Cardiol* 2007;**50**:2095–2097.

39. Roy P, Torguson R, Okabe T, Pinto Slottow TL, Steinberg DH, Smith K, Xue Z, Satler LF, Pichard AD, Waksman R. Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents. *J Interv Cardiol* 2007;**20**:307–313.
40. Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. *JAMA* 2013;**310**:189–198.
41. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. *Am Heart J* 2010;**160**:1035–1041, 1041 e1031.
42. Mehran R, Baber U, Steg Ph G, Ariti C, Weisz G, Witztzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet* Published online September 1, 2013. [http://dx.doi.org/10.1016/S0140-6736\(13\)61720-1](http://dx.doi.org/10.1016/S0140-6736(13)61720-1).
43. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. *Eur Heart J* 2012;**33**:3078–3087.
44. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Harrington RA. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. *J Am Coll Cardiol* 2006;**47**:809–816.
45. Ong AT, Hoyer A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. *J Am Coll Cardiol* 2005;**45**:947–953.
46. Airolidi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. *Circulation* 2007;**116**:745–754.
47. Schulz S, Schuster T, Mehili J, Byrne RA, Ellert J, Massberg S, Goedel J, Bruskin O, Ulm K, Schomig A, Kastrati A. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. *Eur Heart J* 2009;**30**:2714–2721.
48. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schomig A, Mehili J, Intracoronary S. Angiographic results: test efficacy of 3 limus-eluting stents I. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the intracoronary stenting and angiographic results: test efficacy of 3 limus-eluting stents (ISAR-TEST-4) trial. *Eur Heart J* 2009;**30**:2441–2449.
49. Hezi-Yamit A, Sullivan C, Wong J, David L, Chen M, Cheng P, Shumaker D, Wilcox JN, Udipi K. Impact of polymer hydrophilicity on biocompatibility: implication for des polymer design. *J Biomed Mat Res Part A* 2009;**90**:133–141.
50. Udipi K, Chen M, Cheng P, Jiang K, Judd D, Caceres A, Melder RJ, Wilcox JN. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. *J Biomed Mat Res Part A* 2008;**85A**:1064–1071.
51. Kim JS, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation. *International J Cardiovasc Imaging* 2012;**28**:1281–1287.
52. Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, Hong MK, Cho YK, Nam CW, Hur SH, Choi JH, Song YB, Hahn JY, Choi SH, Gwon HC, Jang Y. Comparison of neointimal coverage between zotarolimus-eluting stent and everolimus-eluting stent using optical coherence tomography (cover OCT). *Am Heart J* 2012;**163**:601–607.